S206: OBINUTUZUMAB PLUS CHEMOTHERAPY DEMONSTRATES LONG-TERM BENEFIT OVER RITUXIMAB PLUS CHEMOTHERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA: FINAL ANALYSIS OF THE GALLIUM STUDY

• W. Townsend,
• W. Hiddemann,
• C. Buske,
• G. Cartron,
• D. Cunningham,
• M. J. Dyer,
• J. Gribben,
• E. Phillips,
• M. Dreyling,
• J. F. Seymour,
• A. Grigg,
• T.-Y. Lin,
• X.-N. Hong,
• D. Kingbiel,
• T. G. Nielsen,
• A. Knapp,
• M. Herold,
• R. Marcus

Affiliations

W. Townsend

1 Cancer Research UK and UCL Cancer Trials Centre, University College Hospitals London, London, United Kingdom

W. Hiddemann

2 Ludwig-Maximilians-University Hospital Munich, Munich

C. Buske

3 Universtitätsklinikum Ulm, Ulm, Germany

G. Cartron

4 CHU Montpellier, Montpellier, France

D. Cunningham

5 Royal Marsden Hospital, Sutton

M. J. Dyer

6 Ernest and Helen Scott Haematological Research Institute, University of Leicester, Leicester

J. Gribben

7 Barts Cancer Institute, Queen Mary University of London, London

E. Phillips

8 University of Manchester, The Christie Hospital and National Institutes of Health Research Manchester Biomedical Research Centre, Manchester, United Kingdom

M. Dreyling

2 Ludwig-Maximilians-University Hospital Munich, Munich

J. F. Seymour

9 Peter MacCallum Cancer Centre and the Royal Melbourne Hospital, Melbourne

A. Grigg

10 Austin Hospital, Austin, Australia

T.-Y. Lin

11 Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, and Collaborative Innovation Center for Cancer Medicine, Guangzhou

X.-N. Hong

12 Fudan University Shanghai Cancer Center, Shanghai, China

D. Kingbiel

13 F. Hoffmann-La Roche Ltd, Basel, Switzerland

T. G. Nielsen

13 F. Hoffmann-La Roche Ltd, Basel, Switzerland

A. Knapp

13 F. Hoffmann-La Roche Ltd, Basel, Switzerland

M. Herold

14 HELIOS-Klinikum Erfurt, Erfurt, Germany

R. Marcus

15 Kings College Hospital, London, United Kingdom